Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
Conditions: Recurrent Solid Tumor; Recurrent Ewing Sarcoma; Recurrent Hepatoblastoma; Recurrent Malignant Germ Cell Tumor; Recurrent Malignant Solid Neoplasm; Recurrent Neuroblastoma; Recurrent Osteosarcoma; Recurrent Peripheral Primitive Neuroectodermal Tumor; Recurren t Rhabdoid Tumor; Recurrent Rhabdomyosarcoma; Recurrent Soft Tissue Sarcoma; Recurrent Wilms Tumor; Refractory Ewing Sarcoma; Refractory Hepatoblastoma; Refractory Malignant Germ Cell Tumor; Refractory Malignant Solid Neoplasm; Refractory Neuroblastoma; Refractory Osteosarcoma; Refractory Peripheral Primitive Neuroectodermal Tumor; Refractory Rhabdoid Tumor; Refractory Rhabdomyosarcoma; Refractory Soft Tissue Sarcoma Interventions: Drug: Onivyde; Drug: Talazoparib; Drug: Temozolomide Sponsors: St. Jude Children's Research Hospital; Pfizer; Ipsen Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Bone Cancers | Brain | Cancer & Oncology | Children | Ewing's Sarcoma | Hepatoblastoma | Hospitals | Neuroblastoma | Neurology | Osteosarcoma | Pfizer | Research | Rhabdomyosarcoma | Sarcomas | Study | Temodar